Welcome to our dedicated page for Chinook Therapeutics news (Ticker: KDNY), a resource for investors and traders seeking the latest updates and insights on Chinook Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chinook Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chinook Therapeutics's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 13, 2023, Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced the appointment of Robert W. Azelby to its Board of Directors. Azelby, who has over 20 years of executive experience in the biopharmaceutical sector, is expected to provide strategic guidance as Chinook advances its pipeline of precision medicines for kidney diseases. He has previously held senior roles in companies such as Eliem Therapeutics and Alder BioPharmaceuticals, where he successfully led significant financing and sale processes. Chinook's lead program includes atrasentan, a phase 3 drug targeting IgA nephropathy, and ongoing trials for other innovative treatments. The company aims to deliver new therapies to underserved patients with chronic kidney conditions.
Chinook Therapeutics, a biopharmaceutical company focused on kidney diseases, has announced participation in two upcoming investor conferences. The 22nd Annual Needham Virtual Healthcare Conference will feature a presentation on April 17 at 2:15 pm EDT, while the 2023 Bloom Burton & Co. Healthcare Investor Conference will include a fireside chat on April 25 at 10:00 am EDT. Interested parties can access live audio webcasts and archived recordings on the company's website, available for 90 days post-event. Chinook is developing precision medicines for chronic kidney diseases, with key programs focusing on atrasentan for IgA nephropathy and other therapies targeted at severe kidney disorders. The company leverages advanced research techniques to drive drug development.
FAQ
What is the market cap of Chinook Therapeutics (KDNY)?
